{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:02:01Z","timestamp":1793196121623,"version":"4.5.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.det.2019.02.004","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T20:21:35Z","timestamp":1555446095000},"page":"287-295","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Topical and Systemic Modalities for Chemoprevention of Nonmelanoma Skin Cancer"],"prefix":"10.1016","volume":"37","author":[{"given":"Kathleen M.","family":"Nemer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Laurin","family":"Council","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.det.2019.02.004_bib1","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1001\/jamadermatol.2015.1187","article-title":"Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the U.S. population, 2012","volume":"151","author":"Rogers","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.det.2019.02.004_bib2","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S0190-9622(96)90139-5","article-title":"Lifetime risk for development of skin cancer in the U.S. population: current estimate is now 1 in 5","volume":"35","author":"Rigel","year":"1996","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"Suppl 61","key":"10.1016\/j.det.2019.02.004_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2133.146.s61.2.x","article-title":"The epidemiology of skin cancer","volume":"146","author":"Diepgen","year":"2002","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.det.2019.02.004_bib4","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/jso.23155","article-title":"The incidence of metastasis from cutaneous squamous cell carcinoma and the impact of its risk factors","volume":"106","author":"Brougham","year":"2012","journal-title":"J\u00a0Surg Oncol"},{"issue":"2","key":"10.1016\/j.det.2019.02.004_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5826\/dpc.0702a01","article-title":"Epidemiological trends in skin cancer","volume":"7","author":"Apalla","year":"2017","journal-title":"Dermatol Pract Concept"},{"issue":"1","key":"10.1016\/j.det.2019.02.004_bib6","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.sder.2011.01.003","article-title":"New agents for prevention of ultraviolet-induced nonmelanoma skin cancer","volume":"30","author":"Camp","year":"2011","journal-title":"Semin Cutan Med Surg"},{"issue":"5","key":"10.1016\/j.det.2019.02.004_bib7","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1055\/s-0033-1353377","article-title":"Chemoprevention of nonmelanoma skin cancer","volume":"29","author":"Soltani-Arabshahi","year":"2013","journal-title":"Facial Plast Surg"},{"issue":"4","key":"10.1016\/j.det.2019.02.004_bib8","first-page":"195","article-title":"Secondary prevention strategies for nonmelanoma skin cancer","volume":"32","author":"Lopez","year":"2018","journal-title":"Oncology (Williston Park)"},{"issue":"4","key":"10.1016\/j.det.2019.02.004_bib9","first-page":"562","article-title":"Chemoprevention of nonmelanoma skin cancer with systemic retinoids: practical dosing and management of adverse effects","volume":"32","author":"Otley","year":"2006","journal-title":"Dermatol Surg"},{"issue":"2","key":"10.1016\/j.det.2019.02.004_bib10","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jaad.2010.11.062","article-title":"Skin cancer in solid organ transplant recipients: advances in therapy and management: part I. Epidemiology of skin cancer in solid organ transplant recipients","volume":"65","author":"O'Reilly Zwald","year":"2011","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2019.02.004_bib11","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jaad.2010.11.063","article-title":"Skin cancer in solid organ transplant recipients: advances in therapy and management: part II. Management of skin cancer in solid organ transplant recipients","volume":"65","author":"O'Reilly Zwald","year":"2011","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2019.02.004_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1067\/mjd.2002.125579","article-title":"Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management","volume":"47","author":"Berg","year":"2002","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.det.2019.02.004_bib13","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1002\/cncr.24284","article-title":"Actinic keratoses: natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial","volume":"115","author":"Criscione","year":"2009","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.det.2019.02.004_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/cancers8100090","article-title":"Photodynamic therapy for non-melanoma skin cancers","volume":"8","author":"Cohen","year":"2016","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.det.2019.02.004_bib15","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1111\/j.1365-2133.2008.08882.x","article-title":"Guidelines for topical photodynamic therapy: update","volume":"159","author":"Morton","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2019.02.004_bib16","article-title":"British Association of Dermatologists and British Photodermatology Group guidelines for topical photodynamic therapy 2018","author":"Wong","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2019.02.004_bib17","series-title":"Levulan\u00ae Kerastick\u00ae (aminolevulinic acid hcl) for topical solution, 20%. Highlights of prescribing information","year":"2018"},{"issue":"3","key":"10.1016\/j.det.2019.02.004_bib18","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/DSS.0000000000000630","article-title":"Randomized vehicle-controlled study of short drug incubation aminolevulinic acid photodynamic therapy for actinic keratoses of the face or scalp","volume":"42","author":"Pariser","year":"2016","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.det.2019.02.004_bib19","series-title":"Ameluz\u00ae (aminolevulinic acid hydrochloride) gel, 10%. highlights of prescribing information","year":"2016"},{"issue":"10","key":"10.1016\/j.det.2019.02.004_bib20","doi-asserted-by":"crossref","first-page":"25912","DOI":"10.3390\/ijms161025912","article-title":"Combined treatments with photodynamic therapy for non-melanoma skin cancer","volume":"16","author":"Lucena","year":"2015","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.det.2019.02.004_bib21","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s40257-018-0360-y","article-title":"Daylight photodynamic therapy for actinic keratoses","volume":"19","author":"Morton","year":"2018","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"10.1016\/j.det.2019.02.004_bib22","first-page":"800","article-title":"Long-term efficacy data for daylight-PDT","volume":"153","author":"Guti\u00e9rrez Garc\u00eda-Rodrigo","year":"2018","journal-title":"G\u00a0Ital Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.det.2019.02.004_bib23","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/00015550510042868","article-title":"Topical photodynamic therapy for prevention of new skin lesions in renal transplant recipients","volume":"86","author":"Wulf","year":"2006","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"10.1016\/j.det.2019.02.004_bib24","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/TP.0b013e318180731e","article-title":"Photodynamic therapy with methyl aminolevulinate for prevention of new skin lesions in transplant recipients: a randomized study","volume":"86","author":"Wennberg","year":"2008","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.det.2019.02.004_bib25","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/j.1524-4725.2009.01384.x","article-title":"Reduction in the incidence of squamous cell carcinoma in solid organ transplant recipients treated with cyclic photodynamic therapy","volume":"36","author":"Willey","year":"2010","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.det.2019.02.004_bib26","series-title":"Efudex\u00ae (fluorouracil) topical solutions and cream","year":"2004"},{"issue":"5","key":"10.1016\/j.det.2019.02.004_bib27","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1365-4632.2009.04045.x","article-title":"Effectiveness of 5-fluorouracil treatment for actinic keratosis\u2013a systematic review of randomized controlled trials","volume":"48","author":"Askew","year":"2009","journal-title":"Int J Dermatol"},{"issue":"9","key":"10.1016\/j.det.2019.02.004_bib28","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1001\/jamadermatol.2015.0502","article-title":"Long-term efficacy of topical fluorouracil cream, 5%, for treating actinic keratosis: a randomized clinical trial","volume":"151","author":"Pomerantz","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.det.2019.02.004_bib29","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.jid.2016.12.029","article-title":"5-Fluorouracil for actinic keratosis treatment and chemoprevention: a randomized controlled trial","volume":"137","author":"Walker","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"issue":"2","key":"10.1016\/j.det.2019.02.004_bib30","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1001\/jamadermatol.2017.3631","article-title":"Chemoprevention of basal and squamous cell carcinoma with a single course of fluorouracil, 5%, cream: a randomized clinical trial","volume":"154","author":"Weinstock","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.det.2019.02.004_bib31","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s13555-015-0082-5","article-title":"5-Fluorouracil \u201cchemowraps\u201d in the treatment of multiple actinic keratoses: a Norwich experience","volume":"5","author":"Goon","year":"2015","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"7","key":"10.1016\/j.det.2019.02.004_bib32","first-page":"685","article-title":"Chemowraps as an adjuvant to surgery for patients with diffuse squamous cell carcinoma of the extremities","volume":"7","author":"Mann","year":"2008","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"4","key":"10.1016\/j.det.2019.02.004_bib33","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/ajd.12055","article-title":"5% Fluorouracil chemowraps in the management of widespread lower leg solar keratoses and squamous cell carcinoma","volume":"54","author":"Tallon","year":"2013","journal-title":"Australas J Dermatol"},{"issue":"1","key":"10.1016\/j.det.2019.02.004_bib34","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1172\/JCI89820","article-title":"Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy","volume":"127","author":"Cunningham","year":"2017","journal-title":"J\u00a0Clin Invest"},{"issue":"4","key":"10.1016\/j.det.2019.02.004_bib35","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jaad.2009.06.020","article-title":"Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles","volume":"62","author":"Hanke","year":"2010","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2019.02.004_bib36","series-title":"Aldara\u00ae (imiquimod) cream, 5%. Highlights of prescribing information","year":"2010"},{"issue":"4","key":"10.1016\/j.det.2019.02.004_bib37","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1001\/archderm.141.4.467","article-title":"Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials","volume":"141","author":"Korman","year":"2005","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.det.2019.02.004_bib38","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.jaad.2006.01.055","article-title":"Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen's disease): a randomized, double-blind, placebo-controlled trial","volume":"54","author":"Patel","year":"2006","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.det.2019.02.004_bib39","first-page":"600","article-title":"Diclofenac sodium 3% gel for the management of actinic keratosis: 10+ years of cumulative evidence of efficacy and safety","volume":"11","author":"Martin","year":"2012","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"10","key":"10.1016\/j.det.2019.02.004_bib40","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/archderm.1997.03890460061007","article-title":"An open study to assess the efficacy and safety of topical 3% diclofenac in a 2.5% hyaluronic acid gel for the treatment of actinic keratoses","volume":"133","author":"Rivers","year":"1997","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.det.2019.02.004_bib41","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1046\/j.1365-2133.2002.04561.x","article-title":"Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel","volume":"146","author":"Rivers","year":"2002","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.det.2019.02.004_bib42","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1684\/ejd.2010.1010","article-title":"Results of a randomized, placebo-controlled safety and efficacy study of topical diclofenac 3% gel in organ transplant patients with multiple actinic keratoses","volume":"20","author":"Ulrich","year":"2010","journal-title":"Eur J Dermatol"},{"issue":"9","key":"10.1016\/j.det.2019.02.004_bib43","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1080\/17425255.2018.1508449","article-title":"Pharmacokinetic and pharmacodynamic evaluation of ingenol mebutate for the treatment of actinic keratosis","volume":"14","author":"Stockfleth","year":"2018","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"11","key":"10.1016\/j.det.2019.02.004_bib44","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1056\/NEJMoa1111170","article-title":"Ingenol mebutate gel for actinic keratosis","volume":"366","author":"Lebwohl","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.det.2019.02.004_bib45","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1200\/JCO.1995.13.8.1933","article-title":"Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study","volume":"13","author":"Bavinck","year":"1995","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.det.2019.02.004_bib46","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1046\/j.1440-0960.2002.00613.x","article-title":"Acitretin for chemoprevention of non-melanoma skin cancers in renal transplant recipients","volume":"43","author":"George","year":"2002","journal-title":"Australas J Dermatol"},{"issue":"3","key":"10.1016\/j.det.2019.02.004_bib47","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1067\/S0190-9622(03)01831-0","article-title":"Acitretin treatment of premalignant and malignant skin disorders in renal transplant recipients: clinical effects of a randomized trial comparing two doses of acitretin","volume":"49","author":"de S\u00e9vaux","year":"2003","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"Suppl 1","key":"10.1016\/j.det.2019.02.004_bib48","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1159\/000248870","article-title":"Long-term retinoid therapy is needed for maintenance of cancer chemopreventive effect","volume":"175","author":"Peck","year":"1987","journal-title":"Dermatologica"},{"issue":"3","key":"10.1016\/j.det.2019.02.004_bib49","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1365-2133.2005.07087.x","article-title":"Reduction of immunosuppression for transplant-associated skin cancer: expert consensus survey","volume":"154","author":"Otley","year":"2006","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.det.2019.02.004_bib50","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/ajd.12631","article-title":"Nicotinamide for skin cancer chemoprevention","volume":"58","author":"Damian","year":"2017","journal-title":"Australas J Dermatol"},{"issue":"5","key":"10.1016\/j.det.2019.02.004_bib51","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1038\/jid.2011.459","article-title":"Oral nicotinamide reduces actinic keratoses in phase II double-blinded randomized controlled trials","volume":"132","author":"Surjana","year":"2012","journal-title":"J\u00a0Invest Dermatol"},{"issue":"17","key":"10.1016\/j.det.2019.02.004_bib52","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1056\/NEJMoa1506197","article-title":"A\u00a0phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention","volume":"373","author":"Chen","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.det.2019.02.004_bib53","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0041-008X(03)00301-6","article-title":"Cyclooxygenases in the skin: pharmacological and toxicological implications","volume":"192","author":"Lee","year":"2003","journal-title":"Toxicol Appl Pharmacol"},{"issue":"1","key":"10.1016\/j.det.2019.02.004_bib54","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1562\/0031-8655(2002)076<0073:CEIMAH>2.0.CO;2","article-title":"Cyclooxygenase-2 expression in murine and human nonmelanoma skin cancers: implications for therapeutic approaches","volume":"76","author":"An","year":"2002","journal-title":"Photochem Photobiol"},{"issue":"5","key":"10.1016\/j.det.2019.02.004_bib55","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/(SICI)1097-0215(20000601)86:5<667::AID-IJC10>3.0.CO;2-Y","article-title":"Enhanced expression of cyclooxygenase (COX)-2 in human skin epidermal cancer cells: evidence for growth suppression by inhibiting COX-2 expression","volume":"86","author":"Higashi","year":"2000","journal-title":"Int J Cancer"},{"issue":"19","key":"10.1016\/j.det.2019.02.004_bib56","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1002\/cncr.27406","article-title":"Nonsteroidal anti-inflammatory drugs and the risk of skin cancer: a population-based case-control study","volume":"118","author":"Johannesdottir","year":"2012","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.det.2019.02.004_bib57","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/ijc.29357","article-title":"Nonsteroidal anti-inflammatory drugs and the risk of nonmelanoma skin cancer","volume":"137","author":"Reinau","year":"2015","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.det.2019.02.004_bib58","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jaad.2010.05.042","article-title":"Analgesic and nonsteroidal anti-inflammatory use in relation to nonmelanoma skin cancer: a population-based case-control study","volume":"65","author":"Torti","year":"2011","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2019.02.004_bib59","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.jaad.2005.05.049","article-title":"Nonsteroidal anti-inflammatory drugs and the risk of actinic keratoses and squamous cell cancers of the skin","volume":"53","author":"Butler","year":"2005","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.det.2019.02.004_bib60","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1002\/ijc.21878","article-title":"Effect of NSAIDs on the recurrence of nonmelanoma skin cancer","volume":"119","author":"Grau","year":"2006","journal-title":"Int J Cancer"},{"issue":"24","key":"10.1016\/j.det.2019.02.004_bib61","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1093\/jnci\/djq442","article-title":"Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial","volume":"102","author":"Elmets","year":"2010","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"10","key":"10.1016\/j.det.2019.02.004_bib62","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1111\/j.1524-4725.2009.01277.x","article-title":"Management of carcinoma of the skin in solid organ transplant recipients with oral capecitabine","volume":"35","author":"Endrizzi","year":"2009","journal-title":"Dermatol Surg"},{"issue":"4","key":"10.1016\/j.det.2019.02.004_bib63","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/dsu.12049","article-title":"Capecitabine to reduce nonmelanoma skin carcinoma burden in solid organ transplant recipients","volume":"39","author":"Endrizzi","year":"2013","journal-title":"Dermatol Surg"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863519300154?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863519300154?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:42:19Z","timestamp":1760006539000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863519300154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":63,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0733863519300154"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2019.02.004","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Topical and Systemic Modalities for Chemoprevention of Nonmelanoma Skin Cancer","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2019.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}